This data note examines the effects of rising EpiPen prices on Medicare and beneficiaries. We analyze EpiPen spending, in the aggregate and per user, in Medicare Part D between 2007 (the year after the Part D drug benefit took effect, and the year Mylan acquired the product) and 2014 (the most recent year of data available).
- view as grid
- view as list
This issue brief provides a landscape of the status of U.S. funding for Zika, a mosquito-transmitted infection that in pregnant women can cause microcephaly as well as other serious birth defects. The brief compares the Congressionally approved Zika funding levels, which provides $1.1 billion to the Zika response, to the President’s February 22nd request, the House and Senate bills that passed each chamber in May, and a Conference Agreement that had been approved by the House in June, but was blocked in the Senate and opposed by the Administration.
Web Event: Rx Drugs and the U.S. Health System: A Conversation about Medicare Prescription Drug Costs
On Wednesday, September 7, from noon to 1 p.m. ET, the Kaiser Family Foundation hosted a web conversation to discuss trends in Medicare prescription drug spending, as well as proposals to reduce costs and forecasts of what beneficiaries can expect in coming years.
Zika, a mosquito-transmitted infection that in pregnant women can cause microcephaly as well as other serious birth defects, has recently become a global challenge, and with the first cases of local transmission now reported in the U.S., a domestic one as well. No new funding for Zika has yet been appropriated…
This brief provides an overview of the implementing organizations that received U.S. global health funding from the U.S. Agency for International Development (USAID) in FY 2015.
This issue brief examines the latest facts about Medicare spending and financing, includes the most recent historical and projected Medicare spending data from the Centers for Medicare and Medicaid Services (CMS) Office of the Actuary (OACT), the 2016 annual report of the Boards of Medicare Trustees, and the 2016 Medicare baseline and projections from the Congressional Budget Office (CBO). It discusses historical and projected spending trends, program financing, Medicare’s financial condition, the Independent Payment Advisory Board (IPAB), and the future outlook.
Premium support is a general term used to describe an approach to reform Medicare that aims to reduce the growth in Medicare spending. These FAQs raise and discuss basic questions about the possible effects of a premium support system for Medicare beneficiaries, the federal budget, health care providers, and private health plans.
With its inclusion in the House GOP health plan released last month, the idea of converting Medicare into a premium support system once again features prominently in Capitol Hill policy discussions about the future of Medicare, the federal health insurance program that covers 57 million seniors and people with disabilities.…
Among beneficiaries who died in 2014, Medicare spent significantly more per person on medical services for seniors in their late sixties and early seventies than on older beneficiaries, according to a new data note from the Kaiser Family Foundation. The analysis comes at a time when physicians can now be…
Medicare Spending at the End of Life: A Snapshot of Beneficiaries Who Died in 2014 and the Cost of Their Care
This data note provides a snapshot of Medicare beneficiaries who died in 2014 and their Medicare spending at the end of life. It examines Medicare per capita spending trends over time since 2000 and in 2014, both overall and by type of service, for beneficiaries in traditional Medicare who died in a given year compared to those who survived the year.